RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price Target
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $175
RBC Capital analyst Shagun Singh Chadha maintains $Johnson & Johnson(JNJ.US)$ with a buy rating, and maintains the target price at $175.According to TipRanks data, the analyst has a success rate of 49
Johnson & Johnson (JNJ.US) has increased the settlement amount for baby powder cancer lawsuits to over $8.2 billion.
According to sources, Johnson & Johnson (JNJ.US) has increased the settlement amount for thousands of lawsuits accusing its baby powder of causing cancer to over $8.2 billion, up from the previous proposed settlement amount of $6.5 billion.
Johnson & Johnson (JNJ) Gets a Buy From RBC Capital
Johnson & Johnson (NYSE:JNJ) Sees Robust Q2 Sales Growth and Strategic FDA Approvals, But Faces MedTech Challenges
Johnson & Johnson (JNJ.US) EGFR/c-Met dual antibody combination chemotherapy approved for second-line treatment of NSCLC
Johnson & Johnson's EGFR/c-Met dual antibody combination therapy has been approved as a second-line treatment for NSCLC.
J&J Said to Boost Offer to Settle Baby Powder Lawsuits to Over $8.2B
The Bank of Japan remains unchanged, providing assistance to the booming global stock market.
The Bank of Japan remains unchanged, indicating that it will not rush to continue tightening monetary policy after the unexpected rate hike in July.
Johnson & Johnson Gets FDA Approval for Non-Small Cell Lung-Cancer Treatment
Express News | FDA Approves Amivantamab-Vmjw With Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer With Egfr Exon 19 Deletions or L858R Mutations
Express News | J&J Lifts Baby Powder Settlement Bid to More Than $8.2 Billion - Bloomberg News
Express News | Johnson & Johnson has increased its offer for baby powder and settlements to over $8.2 billion.
Cantor Fitzgerald Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $215
Cantor Fitzgerald analyst Louise Chen maintains $Johnson & Johnson(JNJ.US)$ with a buy rating, and maintains the target price at $215.According to TipRanks data, the analyst has a success rate of 42.6
Johnson & Johnson Commemorates 50 Years in Singapore With a Series of Events Marking a Remarkable Milestone
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
Citi Maintains Johnson & Johnson(JNJ.US) With Buy Rating
Citi analyst Joanne Wuensch maintains $Johnson & Johnson(JNJ.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 63.8% and a total average return of 6.4% over the
Johnson & Johnson (JNJ) Faces Legal Challenges While Advancing MedTech Innovations for Growth
U.S. To J&J: Don't Target Hospital Drug Discounts -- WSJ
Sector Update: Health Care Stocks Steady Premarket Tuesday
Sector Update: Health Care